key: cord-0739907-0d1azbpp
authors: Jain, Manish; Vadboncoeur, Julie; Garg, Sunir J.; Biswas, Jyotirmay
title: Bacille Calmette-Guérin: An Ophthalmic perspective
date: 2021-07-31
journal: Surv Ophthalmol
DOI: 10.1016/j.survophthal.2021.07.005
sha: 06ee552d2015fd46d995fbf70ce685ed92764eff
doc_id: 739907
cord_uid: 0d1azbpp

Vaccines such as bacille Calmette-Guérin (BCG) are known for their heterologous effects mediated through a number of mechanisms, including trained immunity constituted by monocyte-macrophage based innate immunity. Other events such as direct hematogenous spread and induction of autoimmunity are also described. There has been a resurgent interest in harnessing some of the benefits of trained immunity in the management of COVID-19, even as several specific vaccines have been approved. We summarize the current knowledge of ocular effects of BCG. Potential effect of granulomatous inflammation on angiotensin converting enzyme activity and accentuation of cytokine storm that may result in undesirable ocular and systemic effects are also discussed.

In many parts of the world, tuberculosis (TB) causes significant mortality and morbidity, including deleterious effects to the eye. In areas that have a high prevalence of TB, bacille Calmette-Guérin (BCG) can reduce the incidence of TB. BCG is a live attenuated vaccine derived from Mycobacterium bovis that was developed over a period of 13 years by French bacteriologists Albert Calmette and Camille Guérin 81 .

After an initial setback while trying to produce a homogeneous suspension of bacilli on a glycerin and potato medium and subsequent interruption of a trial on cattle with the outbreak of World War-I, they succeeded in attenuating the bacilli by adding ox bile 20 . The attenuated vaccine was initially termed bacille bilie Calmette-Guérin; over the years "bilie" was dropped, and BCG was agreed on. Oral administration was chosen for human trials since Calmette considered the gastrointestinal tract to be the usual route of natural infection by the tubercle bacillus 81 . Calmette and Guérin were subjected to much criticism in 1930 following the Lübeck disaster during which 72 babies died out of the 251 vaccinated; however, during this trial in 1931, negligent contamination of the vaccine by virulent bacilli in the Lübeck laboratories was proven as the cause, and the vaccine was exonerated 81 . The emergence of tuberculosis following World Word II led to numerous studies proving the usefulness and efficacy of BCG vaccine. Despite its widespread use, BCG has been associated with heterologous effects 59 . Lamm and coworkers reviewed over 1000 publications between 1921 and 1982 that reported 10,000 complications of BCG vaccination 65 . The incidence of ocular side effects is not known as the bulk of information is based on case reports.

Much of our understanding of these adverse effects of BCG comes from its intravesical use (Intravesical BCG, IBCG) in cancer immunotherapy, during which multiple cycles of BCG vaccine are administered.

Additionally, BCG is used as an immunomodulator in the treatment of melanoma. Applications in conjunctival malignancies have also been explored.

In contrast, the potential beneficial impact of BCG vaccine to reduce all cause mortality has been significant 6,45,51,B,54,116 . A decrease in mortality from infectious agents other than tuberculosis such as bacteria (Staphylococcus aureus), fungi (Candida albicans), and viruses (yellow fever viruses) had prompted researchers to explore the immunologic basis of these effects 62, 63 . A resurgent interest in harnessing the beneficial effects of BCG vaccine is also based on the epidemiological patterns of corona virus disease and different national BCG vaccination policies C , though a maladjusted immune system could also result in immunopathology 70 . The above scenario in the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic, prompted us to review the ophthalmic adverse effects of BCG including both infectious and immune-mediated mechanisms. Meanwhile, six vaccines are approved by the WHO for emergency use against COVID-19. These are produced by Pfizer BioNTech, Moderna, Janssen, AstraZeneca/Oxford, Sinopharm and Sinovac. The first three of these are also approved by the USFDA D,E .

Innate immunity, constituted by the monocyte-macrophage system, provides the primary response to mycobacterial infection and results in wider nonspecific "trained immunity" 6, 63, 67, 98 . The evidence for aforementioned trained immunity originates from studies that demonstrated production of higher quantities of cytokines, such as IL-1β, IL-6, IFN-γ and TNF, in response to various infections 6,62-64 .

Heterologous immunity needs a few weeks to develop; instead an epigenetic reprogramming of immune cells that involves methylation of histones has been proposed 62 . These effects remain active even after a year post vaccination. Equally important in the pathogenesis of tubercular diseases are the evasive strategies developed by the mycobacteria 26,124

Ever since Mossmann and coworkers described the differentiation pathways of CD4 + naïve Th0 cells into two different effector cell lines,Th1 and Th2 cells, our understanding of the response of the immune system to different immunologic challenges has evolved significantly 58, 93, 128 . By default, the phagocytosable microbes including mycobacteria lead to a Th1 response, initiated by the release of IL-2.

Subsequently, mature Th1 cells secrete IFN-γ, and LT-α (Fig 1) . As the mycobacteria are destroyed, there is a gradual switch to Th2 response through multiple cell divisions 58 . Apart from stimulating phagocytosis, IFN-γ induces the oxidative burst, intracellular killing of microbes, and expression of class I and class II major histocompatibility complex (MHC) molecules on a variety of cells, such as endothelial cells, keratinocytes, and fibroblasts. They also stimulate adhesion molecule expression on endothelial cells 38, 58, 78, 98, 133 .

In contrast, Th2 response is the default response to large non-phagocytosable, extracellular pathogens such as helminthes (Fig 1) . Th2 cells secrete IL-4, IL-5, IL-9, IL-10, and IL-13. There is a considerable overlap in the pattern of cytokines secreted by Th1 and Th2 cells especially IL-10 and IL-13. Because of this overlap, the two responses are conventionally described by their ability to secrete either IFN-γ or IL-4. The culmination of Th2 response is B cell proliferation, antibody production, and eventual switch from IgG to IgE antibodies. IgE titers reflect an indirect measure of Th2 activity implicated in allergic and atopic reactions. Interestingly, Th1 and Th2 cells cross-regulate one another and can be influenced by pharmacological interventions or vary during the phases of evolution of an infectious disease 75, 78, 131 . In the case of leprosy, the paucibacillary tuberculoid leprosy is a manifestation of an aggressive Th1 response, while the lepromatous end of leprosy is dominated by a Th2 response 141, 142 . A similar dichotomy is evident in immune responses against Mycobacterium tuberculosis 82, 83 . Therefore, patients with active tuberculosis have a poor cell-mediated response, delayed hypersensitivity reaction, and a decreased cell proliferation and IFN-γ production in response to tuberculin or purified protein derivative (PPD); rather these patients exhibited higher IL-4 82 . An effective Th1 response is clinically evident in Type IV or delayed hypersensitivity, while Th2 response is seen in Immediate or Type I hypersensitivity.

Over a century, the BCG vaccine has been administered to more than three billion children in the Expanded Programme on Immunization (EPI) across all regions 152 . Globally single-dose BCG vaccine is administered to approximately 100 million newborns each year F . A British study reported 50% protection that lasted 20 years 86 . Although BCG has contributed to reducing both the infant tuberculosis-related mortality, as well as general childhood mortality, its efficacy among adults in preventing TB varies between 0-80%, 3 and there is no good evidence that it lasts more than 10 years post vaccination. 129 An exception is the native Alaskan Indian community where it lasts for over 50 years 5 . Conversely, complete lack of protection has also been cited in an endemic zone in India 7,91 . Substrain variability, host genetics, nutritional status, and presence of helminthes co-infections have been considered as explanations of differential efficacy 90, 91, 92, 102, 106 . Additionally, suppression of T lymphocytes by TGF-β and IL-10 produced by regulatory T cells (Tregs) in response to environmental mycobacteria has been suggested. Environmental mycobacteria can have a masking or blocking effect. Palmer and colleagues suggested that exposure to various environmental mycobacteria could itself provide some protection against tuberculosis and affect the immune system in various ways, thus masking the effect of BCG 106 . In contrast, the blocking effect implies that the prevailing cell-mediated immunity to environmental mycobacteria eliminates the attenuated bacilli following BCG inoculation 109 . Further, neonates' immature immune system readily switches from the naïve Th0 status to Th1 or Th2 unlike adults who have an established Th1/Th2 profile 110 .

Of the 21 substrains developed from the initial strain, the Denmark/Copenhagen strain 1331, Russian/Moscow, Japanese/Tokyo 172 BCG, Pasteur 1173 P2 and the Moreau RDJ strains account for more than 90% of BCG vaccines administered globally 30,F . The Pasteur 1173 P2 and Danish 1331 strains appear to induce more adverse events G .

The above understanding of antimycobacterial immunity is clinically relevant. Ocular tuberculosis does not have a diagnostic gold standard, and many cases continue to be presumptive. Differentiating TB from sarcoid anergy remains challenging. Further, the pattern of tubercular ocular inflammation may be different in immune-compromised or immune-suppressed patients. Because of its slow growth rate, culture takes up to ten days, causing delay in the institution of antitubercular therapy. While polymerase chain reaction and interferon-gamma release assays (IGRA) are available, health care systems in low to moderate income countries continue to rely on the PPD-based Mantoux test. Unlike IGRA, the Mantoux test can potentially re-boost delayed hypersensitivity or alter the immunologic milieu 18 .The subsequent impact on ocular inflammation has not been overtly studied, except for isolated case reports 18,33 .

Further, BCG vaccination too can lead to a positive Mantoux test. Many instances of paradoxical worsening of ocular inflammation with antitubercular drugs are reported ,21,66 . The increased availability of tubercular antigens from hasty killing of mycobacteria or improved immune status leads to phenomenon such as immune reconstitution inflammatory syndrome (IRIS), also called immune recovery uveitis (IRU), following highly active antiretroviral therapy 12, 50 . Conversely, a primary immune mediated ocular inflammation sometimes progresses to an infectious entity 85 . Similar phenomena are observed in the reversal patterns of leprosy and in Jarisch-Herxheimer reaction of syphilis 19, 140, 141 . Thus, the role of aggravated Th1 response is not ruled out on re-challenge with PPD.

A large study from Brazil did not find any statistically significant difference in the rate of adverse events with revaccination as compared to primary vaccination 35 . Similarly, studies from Malawi and Brazil found no evidence of enhanced protection against TB through revaccination 8, 60 . At the time of writing, there are twenty trials studying the protective effects of BCG vaccination, of which 11 involve healthcare workers H . World Health Organization's Strategic Advisory Group of Experts on Immunization (SAGE) does not currently approve BCG for such protection; nevertheless, the outcome of above studies will be pertinent with regards to future pandemics.

William Coley, considered as the father of modern cancer immunotherapy, described the potential role of microorganisms in immunotherapy after witnessing regression of sarcoma in patients with erysipelas caused by Streptococcus pyogenes 28 . An autopsy study reported a lower incidence of malignancies among those who had BCG vaccination 88 . Alvaro Morales described the use of BCG in cancer immunotherapy in 1976 92 ; however, its mechanism unfolded slowly 87 . The use of BCG therapy to reduce tumor burden following its resection depends on the ability to get live bacteria proximal to the malignancy and a deranged glycosaminoglycan layer allowing for better immunologic access to the tumor 112 .Additionally, antigen 85 and fibronectin attachment protein (FAP) expressed by BCG facilitate specific receptor-ligand-mediated attachment to the urothelium. Once attached, the BCG induces expression of the MHC class II molecules on urothelial cells enabling them to function as antigenpresenting cells (APC) 107 . Moreover, there is robust production of cytokines such as IL-6, IL-8, GM-CSF and TNF-α. These events lead to the formation of epithelioid and giant cell granulomas that contain macrophages, dendritic cells, lymphocytes, neutrophils, and fibroblasts (Fig 2 A & B) 111 .

All high-grade and some low-grade non-muscle invasive bladder cancers (NMIBC), including carcinoma in situ are candidates for IBCG therapy; however, a recent review suggests that only 50% of high-risk patients actually receive it, and primarily because of adverse events, only 16-29% complete the 3 year course of immunotherapy 79 . In another series of 1316 patients on IBCG, 69.5% reported complications that ranged from irritative cystitis to severe systemic sepsis. Of these 62.8% had local and 30.6% had systemic complications 16 . As some patients are non-responders to BCG immunotherapy, and because there is some risk associated with the dissemination of an attenuated bacteria, mycobacterial cell wall extract and mycobacterial cell wall nucleic acid complex have also been explored 71, 105 . Although detailed immunological studies were not carried out, this approach rendered 26.5% of patients with carcinoma in situ and 61.2% of patients with papillary tumors disease-free for at least 1 year with an intact bladder 71 .

Interestingly, cell wall components form part of complete Freund's adjuvant (CFA), which contains inactivated and dried mycobacteria and is used along with emulsified uveitogenic antigens to induce experimental autoimmune uveitis and sympathetic ophthalmia 22,114 ; however, nonspecific immune stimulation with BCG had no protective effect against infectious keratitis 67,94,127 .

Rutgard and coworkers demonstrated subconjunctival administration of BCG organisms in New Zealand albino rabbits without producing toxic effects locally or within the eye 119 . This was the foundation of BCG immunotherapy in ocular experimental tumors 119 . Other investigators observed reduced recurrence of bovine ocular squamous cell carcinoma by repeated intralesional injections of live BCG or BCG cell wall components compared to a previous study by the same group where single injections were used 120 .

Both studies showed that the delayed hypersensitivity to PPD persisted longer in animals that showed tumor regression.

Larson and coworkers had previously demonstrated BCG's role in protection against Herpes virus hominis type 2 administered by vaginal instillation, intracorneal injection, and scarification of the cornea in Dutch-belted and New Zealand rabbits 67 . Following this, Tabbara and coworkers tested BCG's potential to provide nonspecific resistance to microbial ocular infections (Fig. 3 ).One group of rabbits was immunized by intravenous administration of BCG, the second group received a unilateral retrobulbar injection of BCG, and the third group, which served as a control, received a unilateral retrobulbar normal saline injection 130 . Subsequently, experimental toxoplasmic retinochoroiditis was induced by injecting Toxoplasma organisms in the suprachoroidal space. Although Toxoplasma was isolated from chorioretinal tissues in all three groups, the onset of the ocular inflammation varied, and the severity, reduced in the TB groups. Intravenous administration had greater protection compared to the retrobulbar group. Toxoplasma antibodies were detected in only one animal; however, this may be because the innate immune system likely eliminated the organisms. Both mycobacteria and Toxoplasma are intracellular pathogens and evoke a Th1 type immune response 74 .

Castro and coworkers designed a novel rabbit model of ocular inflammation to test the antiinflammatory potential of thalidomide 23 . After two subcutaneous injections of BCG to prime the immune system, they injected BCG intravitreally to induce panuveitis. They demonstrated a rise in the inflammatory proteins N-acetyl-b-glucosaminidase and myeloperoxidase in ocular tissues, which dwindled following a single intravitreal injection of thalidomide. The authors also confirmed the response with electrophysiology and histopathology. Further evidence of autoimmunity induced by BCG comes from studies on cases of reactive arthritis 10 . It is an immune-mediated syndrome triggered by autoreactive T lymphocytes induced by bacterial fragments such as LPS and nucleic acids. The prevalence of HLA-B27 in reactive arthritis varied between 30% and 50% 10,A . Cross-reactivity between mycobacterial antigens, particularly the 65-kD heat-shock protein, and HLA-B27 tissue antigen had also been discussed 139 . Of four cases in the English literature, three developed reactive arthritis after the fourth cycle of BCG, and the other after the fifth cycle 50, 53, 107, 121 . This probably underlines a prerequisite of recurring booster effect. One of these cases tested positive for both HLA-B27 and HLA-DR4 53 . HLA-DR4 is associated with high responsiveness to mycobacterial antigens 103 . Idiopathic retinal vasculitis is another entity often thought to have tubercular association that is associated with HLA-B51, HLA-DR1 and HLA-DR4 14 . Nevertheless, many uveitic entities associated with tuberculosis are noninfectious and driven by consequential autoimmune mechanisms 36 .

The spectrum of ocular inflammation associated with BCG includes both infectious and immunemediated diseases 79 . Based on the Naranjo scoring system, these associations are classified as definite 80.96,97 .

Many historic accounts appeared in the literature shortly after the introduction of BCG vaccination 4, 39, 56, 76, 89, 132 . Although many features of these illnesses resembled the current description of conditions associated with ocular tuberculosis 47 , the limitation of these studies was poor feasibility of appropriate work up or availability of vitreous samples in the "pre-vitrectomy era". Miettinen described events (49%) as tubercular in origin while the rest 76 events (51%) were presumed tubercular associations. His astute observations included both infectious and noninfectious conditions ( Table 1) . As the prevalence of tuberculosis in Europe was presumably higher, some of these cases could be caused by infection with M. tuberculosis itself rather than dissemination of M. bovis through vaccination 133 . Some of these events described by Miettinen developed fairly quickly after vaccination, with the earliest reported case one day after vaccination 88 . His contemporary Damato reported 11 cases in Malta in children between 4 to 8 years of age within 2 to 6 weeks post vaccination 32 . He mentioned two other cases and concluded that the sudden surge in the incidence of this otherwise rare entity implied the induction of a clinically useful immunity by BCG. Children in this cohort had tested negative to PPD before vaccination, giving further credence to Miettinen's putative association.

In recent years with the use of IBCG, new associations were described: Liu and coworkers mentioned only 15 cases of ocular inflammation following IBCG 79 . Buchs, on the other hand published a much higher proportion of ocular inflammation, with as many as 25% of cases 17 .

Tinazzi and coworkers conducted a systematic review of reactive arthritis following IBCG instillation and reported that 24% of cases developed ocular involvement, excluding 2% who had Sjögren syndrome 132 .

Ng and coworkers described a case of urethral discharge, bilateral conjunctivitis, and low back pain after the fourth cycle of BCG immunotherapy 99 . Apart from conjunctivitis associated with reactive arthritis, a case of follicular conjunctivitis 24 hours following accidental spillage of BCG vaccine on a healthcare worker is reported 113 . During attempted intradermal injection of BCG vaccine into a struggling neonate's upper arm, the syringe slipped out of the infant's skin discharging its contents into the injector's eye. In view of previous BCG vaccination, the response was considered as a manifestation of delayed hypersensitivity. The doctor was treated with topical steroids along with a one-month course of oral isoniazid. Similarly, a case of BCG reactivation with concurrent mucocutaneous involvement including conjunctivitis was described in an infant two months following BCG vaccination, and this was in association with Kawasaki disease 40 .

Chakraborty and coworkers reported a case of bilateral symmetrical corneal ulceration with mucopurulent conjunctivitis and dry eye following the fourth dose of IBCG 24 . The case went on to have a bilateral descemetocele and ocular perforation. They did not isolate acid-fast bacilli on culture and considered it as an immune-mediated response. There are no reports of molecular mimicry or sequence homology between tubercular and corneal antigens.

In a study of 256 subjects treated with IBCG, 4.3% had disseminated systemic infection 110 Dogan described two cases of Vogt-Koyanagi-Harada (VKH) disease following four cycles of IBCG 33 . One of these had a previous history of tuberculosis and had received antitubercular drugs for nine months. Sequential re-challenge likely led to accentuated immune response. Dogan considered immune dysregulation and subsequent immunological reaction as the underlying mechanism.

Uveitis with vitiligo has also been reported following BCG and tumor infiltrating lymphocyte immunotherapies for malignant melanoma, with an implicit role of autoimmunity targeted against melanocytes 34, 37, 149 . A proinflammatory surge was noted in the aqueous humor 34 autoantibodies to recoverin has also been described 123 .

Vasculitis represents an area with a considerable infectious-autoimmunity overlap. Both infections and vaccinations have been incriminated 112 Interestingly, reactivation and erythema at the BCG inoculation site have been reported in up to 50% of children with Kawasaki disease, predominantly in males preponderance 1, 134 ; Cross-reactivity between mycobacterial heat-shock protein 65-kD (HSP65) and the human homolog is reported as a possible cause of this reactivation 148 . An alternative explanation was a possible reactivation and multiplication of mycobacteria at the inoculation site in an immunocompromised state induced by a viral illness 95 .

Idiopathic retinal vasculitis or Eales' disease (ED) is long thought to be associated with tuberculosis.

Although no difference was found in the humoral and cell mediated immune response to mycobacterial A60 antigen, ED has a shared human leucocyte antigen predisposition (HLAB51, DR4) similar to Behçet's disease and VKH disease 13, 14 . Natural course of this entity can change over time as a previously immunocompetent tuberculin negative ED subject with occlusive vasculitis developed tuberculoma six years after initial presentation 84 .

Yen and coworkers described the first case of a 12-year-old girl who developed reversible bilateral optic neuritis five days after BCG vaccination 147 She was treated as post-infectious cerebral demyelination with intravenous antibiotics, methylprednisolone, and immunoglobulin and showed significant recovery after 2 weeks. An acute, severe, and irreversible response to BCG was reported in a child with multiple sclerosis who developed optic neuritis within half an hour of administration of Mantoux test 77 .

Zaki and coworkers described a 5-year-old boy who developed bilateral reversible optic neuritis following administration of antitubercular drugs despite being off ethambutol 150 The authors considered this to be an immunologically mediated response. Of importance, there is a distinct possibility of reexposure to mycobacterial antigens in this case. Optic neuritis has also been reported in conjunction with anti-TNFα therapy, including monoclonal antibodies 61, 72, 100, 125 . Interestingly, other workers found that BCG vaccination was beneficial in clinically isolated syndromes related to multiple sclerosis in a randomized control trial 29, 118 . Collectively, these reports suggest that multiple factors, including exposure to antigens, molecular mimicry and interplay of cytokines are involved in the induction of optic neuritis. The aggravation with a simple Mantoux test indicates that it may be prudent to use an in vitro test such as IGRA rather than the in vivo tests aimed at quantifying the cell-mediated immunity or delayed hypersensitivity.

Only one case of orbital inflammation following IBCG has been reported in a patient presenting with bilateral chemosis, proptosis and thickened extraocular muscles along with reactive arthritis 131 . Thyroid autoantibody profile of this patient was normal. All inflammatory features abated in response to oral steroids.

Th1 response mediated through pro-inflammatory cytokines such as IL-2, IFN-γ results in granulomatous inflammation 57 . BCG induces an increase in the level of angiotensin-converting enzyme (ACE) levels 73 .

BCG-induced animal models of chronic granulomatous pulmonary inflammation also show enhanced ACE-like activity that determines the intensity of inflammation 122 . Thus, ACE is a molecular marker of BCG-induced granulomatous inflammation in the lung. It is involved in both the innate and adaptive immunity. Over-expression of ACE on neutrophils and macrophages facilitates enhanced immune responses. Similarly, by virtue of its peptidase activity, it is involved in the molecular trimming and display of MHC class I and class II antigens on APCs. As the cells change their ACE production, the peptides they display also change though this may not necessarily result in enhanced immunogenicity 11 .

ACE2 is a transmembrane peptidase 146 . Metalloproteinases cleave this "full length ACE2," and the soluble version is released in the extracellular environment as circulating ACE2. The cellular ACE2 molecule itself acts as the functional receptor for the spike glycoprotein of the human coronavirus HCoV-NL63, SARS-CoV and SARS-CoV-2, while the "abridged version" is part of the protective and counter-regulatory mechanisms 146 . It reduces inflammatory cytokines, protects the cardiovascular system and kidneys, regulates immune responses, and overall protects lungs from SARS-CoV2 infection.

A crucial aspect of the severe COVID-19 disease is the induction of a 'cytokine storm', an umbrella term characterized by higher than normal production of pro-inflammatory cytokines. Wider expression of cellular ACE2 enhances viral entry, but eventually leads to cellular destruction, thus cutting off the supply of free ACE2. ACE2 is then unavailable to play its intended physiological roles that would prevent a cytokine storm and inflammatory damage to multiple organs.

Meanwhile, apart from epidemiological studies, some immunological evidence has accrued that supports the BCG's utility in protection against acute respiratory tract infections in the elderly. This effect seems to emanate from enhanced IFN-γ and IL-10 144 .

While trained immunity induced by BCG has a protective effect on other viral infections, there is a caveat: ACE2 is the molecular docking port for SARS CoV-2 virus entry. Its expression has been demonstrated in alveolar macrophages 150 . Th1 cytokines were significantly elevated in severe cases of COVID-19; GM-CSF and IL-6 induce further monocyte migration and mediate infiltration of inflammatory macrophages and dendritic cells aggravating lung injuries, an effect that can aggravate if the free ACE2 levels were modulated 146, 150 ; IL-6 is a biomarker of progression and severity of COVID-19 135 .

Additionally, the ACE2 is expressed in the heart, kidney, blood vessels, and alveolar epithelium, the other potential targets of the virus 153 . It is also upregulated in the lower airway epithelium of smokers and chronic obstructive pulmonary disease 69 . Wang and coworkers have shown a 5.9-fold increase in the adverse effects of COVID-19 and 63% higher mortality in this group of patients 143 . ACE2 activity is more pronounced in these two groups though the exact risk of developing a cytokine storm is unknown 52,126 .

These diseases and tuberculosis are essentially driven by the monocyte-macrophage system that has a preponderant role in the immunopathology associated with severe outcome in SARS-CoV-2 infection 44 .

Cytokine storm is an excessive and uncontrolled release of pro-inflammatory cytokines that leads to a drop in lymphocytes counts, including CD8 + T cells and natural killer cells 153 Another concern is about the potential risk related to medications that act on the renin-angiotensinaldosterone system, of which ACE is an essential component in patients exposed to Covid-19 31, 85, 115 .

Current evidence suggests that the immune response to BCG varies across populations. Thus, the cytokine response following BCG vaccination is different in Malawian and British infants 64 . Recently, Boer and coworkers have shown that BCG induces a divergent immune response in naïve adults that could be either CD4 + , CD8 + T cells mediated pro-inflammatory (IL-2, IFN-γ and TNF-α) or CD8 + regulatory T cells mediated "virtually absent cytokine" response 15 . Definitive answers to the above complex questions would finally emerge once the outcome of the ongoing trials is known F,H .

Interestingly, sequence homology between several SARS-CoV-2 and BCG epitopes including the envelope protein and the receptor-binding domain of the spike glycoprotein provides an additional mechanistic basis for the potential cross-reactive adaptive immunity 101,137 .

Eyes exhibit a wide range of effects of BCG vaccination that range from innocuous follicular conjunctivitis to bilateral endophthalmitis and optic neuritis. These effects are more commonly seen with IBCG compared to routine immunization, likely due to the more frequent and higher doses involved. While harnessing the potential benefits of trained immunity is tempting, the heterologous ill effects must be kept in mind. With diverse immune responses elicited by BCG, different populations may exhibit different levels of protection or adverse events. Given that the BCG-driven granulomatous response can potentially up-regulate the ACE2 activity, it is a theoretical concern that these patients may be at higher risk for severe COVID-19 infections and resultant cytokine storm. As we await the outcome of ongoing randomized control trials, the medical community needs to be aware of ophthalmic and other effects of BCG. Although many vaccines have been approved for emergency use for COVID-19, the current impetus on trained immunity research may provide a bridging tool in mitigating future zoonotic diseases. Th0 either progresses to a Th1 pathway following an exposure to phagocytosable material such as mycobacteria or Th2 pathway, if a non phagocytosable material such as a parasite is encountered. Subsequent chain of events, the cytokine profile, the activation of monocytemacrophage system, B lymphocyte or mast cell is illustrated. 

Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1

Unusual case of cerebral demyelination and bilateral optic neuritis in an infant with suppurative BCG lymphadenitis

The success and failure of BCG -implications for a novel tuberculosis vaccine

Complications of BCG vaccination with particular reference to ocular reactions

Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study

BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity

Tuberculosis Prevention Trial

Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine

Vaccine-Associated Uveitis

Reactive arthritis induced by intravesical BCG therapy for bladder cancer: our clinical experience and systematic review of the literature

Angiotensin-converting enzyme in innate and adaptive immunity

Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection

Evaluation of lymphocyte proliferation assay to purified protein derivative, enzyme linked immunosorbant assay, and tuberculin hypersensitivity in Eales' disease

Profiling of human leukocyte antigens in Eales' disease

Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults

Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate-and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genitourinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG

Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction

Severe uveitis followed by reactive arthritis after bacillus Calmette-Guérin therapy

The treatment of malignanat tumors by repeated inoculations of erysipelas:with a report of ten original cases

Altered humoral immunity to mycobacterial antigens in Japanese patients affected by inflammatory demyelinating diseases of the central nervous system

The establishment of sub-strain specific WHO reference reagents for BCG vaccine. Vaccine

The ACE-2 in COVID-19: Foe or Friend?

vaccine and phlyctenular kerato-conjunctivitis

Vogt-Koyanagi-Harada disease following BCG vaccination and tuberculosis

Uveitis and vitiligo associated with BCG treatment for malignant melanoma

Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer

Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy

Harnessing the beneficial heterologous effects of vaccination

Chorioretinitis induced by intravesical Bacillus Calmette-Guérin (BCG) instillations for urinary bladder carcinoma

Clinics of ocular tuberculosis

Endophthalmitis from Mycobacterium bovis-bacille

Calmette-Guérin after intravesicular bacille Calmette-Guérin injections for bladder carcinoma

Epididymo-orchitis and Reiter's disease. Two infrequent complications after intravesical bacillus Calmette-Guérin therapy

Bilateral panuveitis and optic neuritis following Bacillus Calmette-Guérin (BCG) vaccination

Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review

Reiter's syndrome following intravesical BCG immunotherapy

Acute lower respiratory infection among Bacille Calmette-Guerin (BCG)-vaccinated children

A case of Intravesical bacillus Calmette-Guerin related endophthalmitis and retinitis confirmed with retinal biposy

Facteur possible de "Tuberculoses atypiques" *BCG, A possible factor of atypical tuberculosis+

A clinicopathological classification of granulomatous disorders

The shift of Th1 to Th2 immunodominance associated with the chronicity of Mycobacterium bovis bacille Calmette-Guérin infection does not affect the memory response

Non-specific immunological effects of selected routine childhood immunisations: systematic review

Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi

Acute Inflammatory Optic Neuritis Associated with a Self-Taper of Oral Prednisone in a Patient Taking Adalimumab

Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes

Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity

BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi

Complications of Bacillus Calmette-Guerin Immunotherapy in 1,278 Patients with Bladder Cancer

Tuberculosis-immune reconstitution inflammatory syndrome

Herpesvirus hominis type 2 infections in rabbits: effect of prior immunization with attenuated Mycobacterium bovis (BCG) cells

Bacillus Calmette-Guerin (BCG) endophthalmitis

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID

Coronavirus infections and immune responses

Efficacy of Mycobacterium Phlei Cell Wall-Nucleic Acid Complex (MCNA) in BCG-Unresponsive Patients. Bladder Cancer

Optic neuritis associated with adalimumab in the treatment of uveitis

Serum angiotensin-converting-enzyme in rabbits with and without pulmonary granulomatosis. Granulomatosis induced with complete-Freund's-adjuvant or BCG

STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis

Immune mechanisms in autoimmune ocular disease

Induced ocular tuberculosis; report of a probable case

Severe irreversible optic neuritis following Mantoux tuberculin skin test in a child with multiple sclerosis--a case report

MHC class II expression and potential antigen-presenting cells in the retina during experimental autoimmune uveitis

Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer

Drug-induced uveitis

History of BCG Vaccine

Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect

Blocking IL-10 enhances Bacillus Calmette-Guerin induced T helper Type 1 immune responses and anti-bladder cancer immunity

Choroidal Tuberculoma Manifesting in A Patient of Eales Disease 6 Years after Initial Presentation

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess

Use of bacille Calmette-Guérin in superficial bladder cancer

Non-tuberculous phlyctenular kerato-conjunctivitis flaring up one day after BCG vaccination; a case report

Errors Observed in the Performance of the Calmette Vaccination in the Light of an Investigation on Eye Tuberculosis Duodecim

Quality Control of BCG Vaccine by WHO: a Review of Factors that May Influence Vaccine Effectiveness and Safety

Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis? Vaccine

A throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

The effect of nonspecific immune stimulation on the recurrence rate of herpetic keratitis in rabbits

Measles infection causing Bacillus Calmette-Guérin reactivation: a case report

A method for estimating the probability of adverse drug reactions

Drug-induced uveitis

Trained immunity: A program of innate immune memory in health and disease

Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations

A review of ocular adverse events of biological anti-TNF drugs

Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine

Vaccines against tuberculosis: where are we and where do we need to go?

Evidence for an HLA-DR4-associated immuneresponse gene for Mycobacterium tuberculosis. A clue to the pathogenesis of rheumatoid arthritis?

An acute disseminated encephalomyelitis case due to mycobacterium tuberculosis

The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer

Effects of Infection with Atypical Mycobacteria on BCG Vaccination and Tuberculosis

Reiter's syndrome after intravesical Bacillus Calmette-Guérin treatment for superficial bladder carcinoma

Bilateral Iritis after Vaccine for Bladder Cancer

How to avoid the impact of environmental mycobacteria towards the efficacy of BCG vaccination against tuberculosis?

Bacillus Calmette-Guerin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a singleinstitution series and review of the literature

Mechanisms of BCG immunotherapy and its outlook for bladder cancer

Autoimmunity in visual loss

Ocular contamination with BCG vaccine

The role of the penetrating wound in the development of sympathetic ophthalmia experimental observations

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Could BCG be used to protect against COVID-19?

Erythema at BCG inoculation Site in Kawasaki disease patients

Effects of Bacille Calmette-Guerin after the first demyelinating event in the CNS

Ocular tolerance of bacillus Calmette-Guerin organisms

Immunotherapy of bovine ocular squamous cell carcinoma by repeated intralesional injections of live bacillus Calmette-Guérin (BCG) or BCG cell walls

Reiter syndrome following intracavitary BCG administration

Increased angiotensin-converting enzyme levels in lung lavage and suppression of inflammation with captopril

Autoimmune retinopathy associated with intravesical BCG therapy

Immunology of Mycobacterium tuberculosis Infections

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy

Cigarette Smoke Exposure and Inflammatory Signaling Increase the Expression of the SARS-CoV-2 Receptor ACE2 in the Respiratory Tract

Effect of immunization with attenuated Mycobacterium bovis (BCG) on experimental herpetic keratitis

Type 1/Type 2 immunity in infectious diseases

Does the efficacy of BCG decline with time since vaccination? Int J Tuberc Lung Dis

Effect of immunization with attenuated Mycobacterium bovis on experimental toxoplasmic retinochoroiditis

Bilateral orbital inflammation following intravesical bacille Calmette-Guérin immunotherapy for bladder cancer

Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review

Conjunctival and cutaneous PPD-tuberculin reactions in 70 patients with eye diseases

Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guérin inoculation site

Interleukin-6 as a potential biomarker of COVID-19 progression

Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma

Identification of similar epitopes between severe acute respiratory syndrome coronavirus-2 and Bacillus Calmette-Guérin: potential for cross-reactive adaptive immunity

Endophthalmitis in a patient treated with Bacillus Calmette-Guerin immunotherapy

The mycobacterial 65 kD heat-shock protein and autoimmune arthritis

Kawasaki-like disease: emerging complication during the COVID-19

The clinical and immunological features of leprosy

Leprosy type 1 (reversal) reactions and their management

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

The efficacy of Bacillus Calmette-Guerin vaccinations for the prevention of acute upper respiratory tract infection in the elderly

Bilateral uveitis after intravesical BCG immunotherapy for bladder carcinoma

ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?

Bilateral optic neuritis following bacille Calmette-Guérin (BCG) vaccination

Presence in Kawasaki disease of antibodies to mycobacterial heat-shock protein HSP65 and autoantibodies to epitopes of human HSP65 cognate antigen

Ocular and systemic autoimmunity after successful tumorinfiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma

Paradoxical response to anti-tubercular treatment

The Comparative Immunological Characteristics of SARS-CoV, MERS-CoV, and SARS-CoV-2 Coronavirus Infections. Front Immunol

The BCG world atlas: a database of global BCG vaccination policies and practices

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

Other cited material

Reactive Arthritis (Reiter Syndrome)

StatPearls

Can a century-old TB vaccine steel the immune system against the new corona virus?

https://www.sciencemag.org/news/2020/03/can-century-old-tb-vaccine-steel-immune-